Report Overview

The UK Hereditary Angioedema (HAE) Therapeutics market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

HAE is a rare inherited disorder characterized by recurrent episodes of the accumulation of fluids outside of the blood vessels, blocking the normal flow of blood or lymphatic fluid and causing rapid swelling of tissues in the hands, feet, limbs, face, intestinal tract, or airway. Usually, this swelling is not accompanied by itching, as it might be with an allergic reaction. Swelling of the gastrointestinal tract leads to cramping. Swelling of the airway may lead to obstruction, a potentially very serious complication.

The symptoms develop as the result of a deficiency or improper functioning of certain proteins that help to maintain the normal flow of fluids through very small blood vessels (capillaries). In some cases, fluid may accumulate in other internal organs. The severity of the disease varies greatly among affected individuals.

Hereditary angioedema is a rare disorder that affects males and females in equal numbers. Symptoms typically begin in early childhood. According to the report, HAE affects between 1/10,000 to 1/50,000 of the population in the UK.



Market Growth Drivers

Intense R&D initiatives by the manufacturers to treat the condition, increasing prevalence of hereditary angioedema and the presence of promising drug pipelines are some more growth factors.

Furthermore, increasing funding for rare genetic diseases and orphan drugs by the government and private companies is also enhancing the interest of the pharmaceutical companies to develop drugs for hereditary angioedema and is fuelling the market growth.

For instance, Recently Takeda Pharmaceutical entered into an agreement for public funding of Takhzyro (lanadelumab), its treatment for eligible HAE patients.

Market Restraints

However, the high cost of treatment and the lack of awareness about HAE is a major reason for misdiagnosis, which in turn, leads to inadequate treatment being provided to patients, which proposes a big challenge for HAE treatment market growth.